Research in context
Evidence before this study
There is no internationally agreed definition of adolescents and young adults (AYAs) for cancer purposes; age ranges of 15–24 years and 15–29 years (at cancer diagnosis) have been used. The US National Cancer Institute proposed defining AYAs as those aged 15–39 years at diagnosis. The European Network for Cancer in Children and Adolescents has adopted this definition and is promoting its use in Europe. Less is known about factors that affect cancer incidence, outcomes, and quality of life in AYAs than other age groups. Furthermore AYAs with cancer have not had the same mortality reduction seen in recent years in younger and older patients with cancer (for some cancers). To try to improve outcomes for AYAs with cancer, various initiatives—including the promotion of collaboration between paediatric and adult oncologists, development of national policies for managing AYAs with cancer, and setting up of AYA-specific treatment units—have been implemented in several European countries. Over the past 5 years population-based analyses of incidence and outcomes for AYAs with cancer have been completed in France, the Netherlands, and the UK. However, the latest survival analysis for Europe as a whole was provided by EUROCARE-4 for patients aged 15–24 years who were diagnosed in 1995–2002.
Added value of this study
The present EUROCARE-5 study provides the latest population-based, 5-year relative survival estimates for European AYAs (aged 15–39 years at diagnosis) compared with children (0–14 years) and adults (40–69 years), diagnosed with cancer in 2000–07. The study also provides survival time trends (1999–2007) for AYAs and children, and assesses whether survival improvements in AYAs still lag behind those in children; and, for the first time to our knowledge, analyses survival differences between AYAs and adults. We found that survival improved during the study period for both AYAs and children with cancer in Europe, and that survival improvements were similar in both these age categories. This finding contrasts with previous results that AYAs lag behind children in terms of survival improvement. However, survival remained significantly worse in AYAs than in children for acute lymphoid leukaemia, acute myeloid leukaemia, Hodgkin's lymphoma, non-Hodgkin lymphoma, astrocytoma, Ewing's sarcoma of bone, rhabdomyosarcoma, and osteosarcoma; and for acute myeloid leukaemia, soft-tissue sarcomas, and fibrosarcomas, survival remained unchanged for AYAs over the study period. These findings are in line with data from earlier time periods (1995–2002).
Implications of all the available evidence
AYAs have worse survival than children for many cancers affecting both groups, justifying initiatives to improve outcomes for adolescents and young adults. For cancers affecting AYAs and children, it has been suggested that AYAs should be treated in an integrated paediatric–adult multidisciplinary setting. This integration would increase the likelihood of inclusion in clinical trails, and improve family and social support. For AYAs with acute lymphoid leukaemia, data clearly indicate that although tumour biology is relatively unfavourable in this group, application of paediatric treatment protocols is feasibile and improves outcomes. However, robust evidence that regimens used to treat children actually benefit AYAs is only available for acute lymphoid leukaemia. Thus, further studies are needed to understand why survival improvements in AYAs lag behind those in children for many important cancers affecting both. The time of these analyses (patients diagnosed in 2000–07, and followed up until at least the end of 2008) pre-dates implementation of European initiatives to improve outcomes, and thus provides important baseline data to evaluate whether initiatives will lead to improved survival in European AYAs with cancer.